Last reviewed · How we verify
NCT06261632
Blood Flow Restriction in Improving Muscle Strength of Patients With Hemophilic Knee Arthropathy
NA trial testing Blood flow restriction in Hemophilia in 40 participants. Status unknown.
28 July 2024
Quick facts
| Lead sponsor | Investigación en Hemofilia y Fisioterapia |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 40 |
| Start date | 19 February 2024 |
| Primary completion | 28 July 2024 |
| Estimated completion | 1 November 2024 |
| Sites | 1 location across Spain |
Drugs / interventions tested
- Blood flow restriction
Conditions studied
- Hemophilia — all drugs for Hemophilia →
Sponsor
Investigación en Hemofilia y Fisioterapia
Who can join
Adults 18 to 60, male only, with Hemophilia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Background. The main physical sequela of patients with hemophilia is the development of a progressive, degenerative intra-articular lesion, known as hemophilic arthropathy). This sequela is manifested by chronic pain, limited range of motion, axial abnormalities, and periarticular muscle atrophy. Objective. To assess the safety and effectiveness of an intervention through blood flow restriction, regarding the frequency of bleeding and the improvement in muscle activation and strength, range of motion, functionality, joint pain, joint status and the perception of quality of life in patients with hemophilic arthropathy. knee and ankle. Study design. Randomized, multicenter, single-blind clinical study. Method. 60 patients with hemophilia A and B will be recruited in this study. Patients will be recruited in 6 regions of Spain. The dependent variables will be: bleeding frequency (self-registration), pain (measured with the visual analog scale and pressure algometer), quality of life (SF-36 scale), joint status (Hemophilia Joint Health Score scale), strength (dynamometer) and muscle activation (surface electromyograph), range of motion (goniometer) and functionality (Timed up and go test). Three evaluations will be carried out: pre-treatment, post-treatment and after a follow-up period of 4 weeks. Expected results. Observe the safety of blood flow restriction in hemophilia patients. To analyze the efficacy of blood flow restriction in improving muscle strength and activation, range of motion, chronic pain, functionality, and the perception of quality of life in patients with hemophilic knee and ankle arthropathy.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Low-Load Quadriceps Strengthening With Blood Flow Restriction in Adults With Haemophilic Knee Arthropathy: A Randomised Controlled Trial.
Villalón-González M, Pérez-Llanes R, López-Pina JA, Cuesta-Barriuso R, et al · · 2026 · PMID 41454588 · DOI 10.1111/hae.70197
Verify or expand the search:
- PubMed search for NCT06261632
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Blood flow restriction
Trials testing the same drug.
- NCT07288905 — Exploring the Effects of Exercise Combined With BFRT on Healthy and Patients With CKD · NA · recruiting
- NCT06261593 — Blood Flow Restriction in Improving Muscle Strength of Patients With Hemophilic Ankle Arthropathy · NA · completed
- NCT05039008 — Restricting Blood Flow in Improving Muscle Strength in Patients With Hemophilic Arthropathy · NA · completed
- NCT05258500 — Strength Training in Hospitalized Patients Using the Ghostly App: a Feasibility Study · NA · completed
- NCT06001944 — Investigation of the Efficacy of Blood Flow Restricted Training in Lateral Elbow Tendinopathy · NA · unknown
Other recruiting trials for Hemophilia
Currently open trials in the same condition.
- NCT07579585 — Effects of Photobiomodulation in Hemophilia Patients. · NA · recruiting
- NCT07406139 — PCC Treatment for Hemophilia Patients With Inhibitor（2022PCC-A） · Phase 4 · recruiting
- NCT07285460 — A Study to Investigate the Efficacy and Safety of Fitusiran Prophylaxis in Male Participants Aged 1 to Less Than 12 Year · Phase 3 · recruiting
- NCT07187661 — Intra-Articular Bevacizumab for Preventing Recurrent Hemarthrosis in Hemophilia With Chronic Synovitis · NA · recruiting
- NCT07099313 — Association of Prophylactic Treatment With Treatment Burden and Psychosocial Variables in Patients With Hemophilia · recruiting
Other Investigación en Hemofilia y Fisioterapia trials
Trials by the same sponsor.
- NCT07516730 — Central Pain Mechanisms and Clinical and Psychological Factors Associated With Pain Interference in Daily Life in Adults · not yet recruiting
- NCT07483541 — Identification of Modifiable Sleep-related Factors in Patients With Systemic Lupus Erythematosus. · not yet recruiting
- NCT07420387 — Effectiveness of an Educational Program for Pain Management in Patients With Hemophilic Arthropathy · NA · not yet recruiting
- NCT07420348 — Incidence of Ultrasonographically Detected Articular Damage in Initially Healthy Joints of Patients With Hemophilia A Re · not yet recruiting
- NCT07123220 — Prognostic Factors for Fatigue in Patients With Systemic Lupus Erythematosus · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06261632 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Investigación en Hemofilia y Fisioterapia
- Last refreshed: 20 February 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06261632.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing